Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy boosts standard treatment for rectal cancer in new trial

NCT ID NCT06312982

Recruiting now Disease control Sponsor: Beijing Friendship Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial is testing whether adding the immunotherapy drug tislelizumab to standard chemoradiation helps people with locally advanced rectal cancer. The study involves 375 participants who will receive either the combination or standard treatment alone. The main goal is to see if the combination leads to a higher rate of complete tumor disappearance and allows more patients to avoid surgery and keep their rectum.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tislelizumab (immunotherapy drug) plus capecitabine and oxaliplatin (chemotherapy drugs)
What this could lead to
If successful, this combination could increase the chance of eliminating the tumor without surgery, allowing patients to keep their rectum and avoid a permanent colostomy.
What could go wrong
This is an early-to-mid stage trial, so the added benefit of tislelizumab is unproven. Immunotherapy can cause immune-related side effects like inflammation of the lungs, gut, or skin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal carcinoma rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED RECTAL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Friendship Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100050, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Beijing Friendship Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100050, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.